The expression and prognostic significance of bcl-2-associated transcription factor 1 in rectal cancer following neoadjuvant therapy
| Autor: | Leslie Samuel, Beatriz Cash, Graeme I. Murray, Gordon T Brown, Ayham Alnabulsi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Histology Colorectal cancer medicine.medical_treatment Kaplan-Meier Estimate Biology Disease-Free Survival GeneralLiterature_MISCELLANEOUS Pathology and Forensic Medicine Bcl-2-Associated Transcription Factor 1 03 medical and health sciences 0302 clinical medicine Internal medicine Biomarkers Tumor medicine Humans Neoadjuvant therapy Aged Proportional Hazards Models Aged 80 and over Rectal Neoplasms Tumor Suppressor Proteins Chemoradiotherapy General Medicine Middle Aged Prognosis medicine.disease Immunohistochemistry Neoadjuvant Therapy Repressor Proteins 030104 developmental biology Biorepository Tissue Array Analysis 030220 oncology & carcinogenesis Biomarker (medicine) Female |
| Zdroj: | Histopathology. 68:556-566 |
| ISSN: | 0309-0167 |
| DOI: | 10.1111/his.12780 |
| Popis: | bcl-2-associated transcription factor 1 (BCLAF1) is a nuclear protein that binds to bcl-related proteins and can induce apoptosis and autophagy. The aim of this study was to investigate the expression of BCLAF1 in a series of rectal cancers following neoadjuvant therapy.Immunohistochemistry was performed on a post-neoadjuvant therapy rectal cancer tissue microarray. It contained rectal cancers (n = 248), lymph node metastases (n = 76), and non-neoplastic rectal mucosal samples (n = 73). A monoclonal antibody against BCLAF1 that we have developed was used. Non-neoplastic rectal epithelium showed nuclear localization of BCLAF1 in both crypt and surface epithelial cells, whereas rectal cancers showed both nuclear and cytoplasmic BCLAF1 expression. Most rectal cancers showed moderate or strong nuclear immunoreactivity, but showed weak cytoplasmic immunoreactivity. Cytoplasmic BCLAF1 expression was increased in primary rectal cancers as compared with non-neoplastic rectal mucosa (P = 0.008). Negative and weak nuclear BCLAF1 expression was associated with a poor prognosis [hazard ratio (HR) 0.502, 95% confidence interval (CI) 0.269-0.939, χ(2) = 4.876, P = 0.027]. Nuclear BCLAF1 expression was independently prognostic in a multivariate model (HR 0.431, 95% CI 0.221-0.840, P = 0.013).This study has shown that both cytoplasmic BCLAF1 expression and nuclear BCLAF1 expression are increased in post-neoadjuvant therapy rectal cancer, and that negative and weak nuclear BCLAF1 expression are independently associated with a poor prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text